UBS AM
LJPC

UBS AM’s La Jolla Pharmaceutical Company LJPC Stock Holding History

UBS AM’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-11,200
Closed -$72K – 2924
2019
Q1 		$72K Hold
11,200
– – ﹤0.01% 2589
2018
Q4 		$106K Hold
11,200
– – ﹤0.01% 2512
2018
Q3 		$225K Sell
11,200
-8,524
-43% -$223K ﹤0.01% 2397
2018
Q2 		$575K Buy
+19,724
New +$609K ﹤0.01% 2035
2017
Q4 		– Sell
-6,100
Closed -$212K – 2663
2017
Q3 		$212K Buy
+6,100
New +$196K ﹤0.01% 2230

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS AM's LJPC Position: Q2 2019 in Review

UBS AM sold out of La Jolla Pharmaceutical Company (LJPC) in Q2 2019, closing a stake of 11,200 shares — an estimated $72K sold.

UBS AM first reported a position in LJPC in Q3 2017 and held it in 5 quarters. The position peaked at $575K in Q2 2018. 80 funds tracked by Wall St. Rank hold LJPC as of Q2 2019.

  • UBS AM reported no remaining La Jolla Pharmaceutical Company position as of Q2 2019 after selling out during the quarter.
  • UBS AM sold 11,200 La Jolla Pharmaceutical Company shares in Q2 2019, an estimated $72K.
  • UBS AM first reported a position in La Jolla Pharmaceutical Company in Q3 2017 and held it in 5 quarters.
  • UBS AM's La Jolla Pharmaceutical Company position peaked at $575K in Q2 2018.
  • 80 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q2 2019.

Based on UBS AM's 13F filing for Q2 2019, filed 15 Aug 2019.